Safety and anti-tumor activity of lisavanbulin administered as 48-hour infusion in patients with ovarian cancer or recurrent glioblastoma: a phase 2a study

Purpose. Lisavanbulin (BAL101553) is the prodrug of avanbulin (BAL27862), a microtubule-destabilizing agent. The goal of this study (NCT02895360) was to characterize the safety, tolerability and antitumor activity of lisavanbulin administered as a 48-hour intravenous (IV) infusion at the recommended...

Descripción completa

Detalles Bibliográficos
Autores principales: Joerger, Markus, Hundsberger, Thomas, Haefliger, Simon, von Moos, Roger, Hottinger, Andreas F., Kaindl, Thomas, Engelhardt, Marc, Marszewska, Michalina, Lane, Heidi, Roth, Patrick, Stathis, Anastasios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140113/
https://www.ncbi.nlm.nih.gov/pubmed/36792805
http://dx.doi.org/10.1007/s10637-023-01336-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10140113/
https://www.ncbi.nlm.nih.gov/pubmed/36792805
http://dx.doi.org/10.1007/s10637-023-01336-9

Ejemplares similares